spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search    

The fully linked HTML version of this article has now been published.
JCS ePress online publication date 7 Mar 2006
doi: 10.1242/jcs.02883

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcs.02883v1
119/7/1283    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spencer, G. J.
Right arrow Articles by Genever, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spencer, G. J.
Right arrow Articles by Genever, P. G.

Research Article

Wnt signalling in osteoblasts regulates expression of the receptor activator of NF{kappa}B ligand and inhibits osteoclastogenesis in vitro


Gary J. Spencer*, Jennifer C. Utting, Sharon L. Etheridge, Timothy R. Arnett, and Paul G. Genever
* Author for correspondence (e-mail: gjs6{at}york.ac.uk)

Reports implicating Wnt signalling in the regulation of bone mass have prompted widespread interest in the use of Wnt mimetics for the treatment of skeletal disorders. To date much of this work has focused on their anabolic effects acting on cells of the osteoblast lineage. In this study we provide evidence that Wnts also regulate osteoclast formation and bone resorption, through a mechanism involving transcriptional repression of the gene encoding the osteoclastogenic cytokine receptor activator of NF{kappa}B ligand (RANKL or TNFSF11) expressed by osteoblasts. In co-cultures of mouse mononuclear spleen cells and osteoblasts, inhibition of GSK3{beta} with LiCl or exposure to Wnt3a inhibited the formation of tartrate-resistant acid phosphatase-positive multinucleated cells compared with controls. However, these treatments had no consistent effect on the differentiation, survival or activity of osteoclasts generated in the absence of supporting stromal cells. Activation of Wnt signalling downregulated RANKL mRNA and protein expression, and overexpression of full-length {beta}-catenin, but not transcriptionally inactive {beta}-catenin {Delta}C(695-781), inhibited RANKL promoter activity. Since previous studies have demonstrated an absence of resorptive phenotype in mice lacking LRP5, we determined expression of a second Wnt co-receptor LRP6 in human osteoblasts, CD14+ osteoclast progenitors and mature osteoclasts. LRP5 expression was undetectable in CD14-enriched cells and mature human osteoclasts, although LRP6 was expressed at high levels by these cells. Our evidence of Wnt-dependent regulation of osteoclastogenesis adds to the growing complexity of Wnt signalling mechanisms that are now known to influence skeletal function and highlights the requirement to develop novel therapeutics that differentially target anabolic and catabolic Wnt effects in bone.


This article has been cited by other articles:


Home page
 BloodHome page
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood, July 15, 2008; 112(2): 374 - 382.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-W. Qiang, Y. Chen, O. Stephens, N. Brown, B. Chen, J. Epstein, B. Barlogie, and J. D. Shaughnessy Jr
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma
Blood, July 1, 2008; 112(1): 196 - 207.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. M. Edwards, J. R. Edwards, S. T. Lwin, J. Esparza, B. O. Oyajobi, B. McCluskey, S. Munoz, B. Grubbs, and G. R. Mundy
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
Blood, March 1, 2008; 111(5): 2833 - 2842.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
V. Delmas, F. Beermann, S. Martinozzi, S. Carreira, J. Ackermann, M. Kumasaka, L. Denat, J. Goodall, F. Luciani, A. Viros, et al.
beta-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development
Genes & Dev., November 15, 2007; 21(22): 2923 - 2935.
[Abstract] [Full Text] [PDF]

Home page
 J. Dent. Res.Home page
C.H. Li and S. Amar
Inhibition of SFRP1 Reduces Severity of Periodontitis
J. Dent. Res., September 1, 2007; 86(9): 873 - 877.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
J. D. Shaughnessy Jr.
Going Against the Grain: Promoting Wnt Signaling to Conquer Cancer
Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 19 - 24.
[Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
P. V. Bodine
Wnt Signaling in Bone
IBMS BoneKEy, March 1, 2007; 4(3): 108 - 123.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Yaccoby, W. Ling, F. Zhan, R. Walker, B. Barlogie, and J. D. Shaughnessy Jr
Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo
Blood, March 1, 2007; 109(5): 2106 - 2111.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
G. A. Clines, K. S. Mohammad, Y. Bao, O. W. Stephens, L. J. Suva, J. D. Shaughnessy Jr., J. W. Fox, J. M. Chirgwin, and T. A. Guise
Dickkopf Homolog 1 Mediates Endothelin-1-Stimulated New Bone Formation
Mol. Endocrinol., February 1, 2007; 21(2): 486 - 498.
[Abstract] [Full Text] [PDF]


© The Company of Biologists Ltd 2006